NeurologyLive® Friday 5 — July 3, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more or watch now buttons for more details and information about each highlight.

1: Streamlining Genetic Screening and Recruitment for an LRRK2-Targeted Parkinson Disease Trial: James Beck, PhD

In a recent interview, James Beck, PhD, chief scientific officer of the Parkinson’s Foundation, discussed how the PD Trial Navigator program helps to identify individuals with Parkinson Disease who may be eligible for the phase 2 NEULARK study. [WATCH TIME: 4 minutes]

2: Recognizing and Addressing Demoralization in Parkinson Disease: Indu Subramanian, MD

In a recent interview at the 2026 ATMRD Congress, Indu Subramanian, MD, a neurologist at UCLA in Los Angeles, California, discussed the growing recognition of demoralization in Parkinson disease. [Watch time: 5 minutes]

3: Clinical Impact of FDA's Expanded Efgartigimod Label: Josh Alpers, MD

In a recent interview following the FDA's expanded approval of efgartigimod, Josh Alpers, MD, a neuromuscular physician at Erlanger Health Systems, discussed the implications for seronegative disease, treatment sequencing, and the evolving definition of antibody-negative MG. [WATCH TIME: 5 minutes]

4: New Deep Learning Tool Forecasts Alzheimer Disease Progression From Baseline MRI

In a recent Q&A, Ashish Raj, PhD, professor of radiology and biomedical imaging at UCSF, discussed a newly developed AI model that predicts current and future cognitive impairment from a single baseline MRI scan in patients across the Alzheimer disease spectrum.

5: Step by Step: UCSF's Real-Time Adaptive DBS Approach for Parkinson Disease

In a recent Q&A, Doris D. Wang, MD, PhD, associate professor of neurological surgery at UCSF, discussed a newly published adaptive deep brain stimulation system that adjusts in real time during walking and what it means for the future of Parkinson disease care.

Don’t have time to read or watch a full video interview? Click here to check out our shorts!